Advanced Micro Devices Inc. sees a better second half of the year ahead, but analysts aren't all sold on management's outlook.
Advanced Micro Devices Inc. sees a better second half of the year ahead, but analysts aren’t all sold on management’s outlook.
Shares of the chipmaker AMD were sliding more than 7% in Wednesday’s premarket trading after AMD posted declining margins for its latest quarter and issued a downbeat outlook for the current one, all while indicating that trends in the second half of the year would improve. The term “second half” came up 36 times on AMD’s call, between management commentary and analyst questions.
See also: ‘AI for us is broader than cloud,’ AMD CEO tells analysts, but chip maker still needs PC recovery to improve margins
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
AMD faces doubts after Intel earnings: Is the bar set too high?Advanced Micro Devices Inc. won't have the dismally low expectations that Intel Corp. had to clear last week when it reports its results.
Weiterlesen »
AMD forecasts second quarter below estimates with slow chip demandAdvanced Micro Devices forecast second-quarter revenue below estimates on Tuesday, showing the chip firms will continue to face challenges as PC sales and the data center market remain weak.
Weiterlesen »
AMD stock is sliding after earnings, and these numbers show whyAMD shares tumbled Tuesday afternoon, as the chip maker reported a big drop in margins and provided a forecast that doesn't suggest immediate improvement.
Weiterlesen »
Super Micro stock pops as earnings beat and forecast shows AI optimismSuper Micro Computer Inc. shares jumped more than 8% in after-hours trading Tuesday, following an earnings report that showed stronger-than-expected earnings...
Weiterlesen »
Uncontrolled Wet AMD: Drug Switch Can Mute Disease ActivitySome patients with uncontrolled neovascular age-related macular degeneration achieved a reduction in disease activity and gains in visual acuity after switching to the biologic agent brolucizumab, according to a new study presented ARVO2023. nAMD
Weiterlesen »
Symptom Severity Linked to Risk for Death in Advanced CancerIdentifying older patients with advanced cancer who have a high risk for hospitalization and death could be a game changer. A new analysis suggests that goal is within reach. OncTwitter
Weiterlesen »